Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Residual tumor thrombus in RCC patients following nephrectomy is a risk factor for VTE, but not for overall survival

Commentary from Professor Susanne Osanto

10th April 2014

A study of the long-term risk of venous thromboembolism (VTE) reported in the Journal of Thrombosis and Haemostasis by Dr. Ihadaddene et al suggests that residual tumor thrombus in RCC patients post-nephrectomy does not predict poor survival. 

Of the 170 stage III-IV surgical renal cell carcinoma patients who underwent nephrectomy 97 (57.1%) had tumor thrombus. Patients with residual tumor thrombus following surgery had a markedly higher risk of developing venous thromboembolism (VTE) during a 2 year follow-up period than those with complete tumor thrombus resection (Hazard Ratio (HR): 8.7; 95% CI: 1.7 to 43.4), and no tumor thrombus (HR: 6.5; 95% CI: 1.7 to 24.7). Importantly, patients with residual tumor thrombus had no worse overall survival. Based on the high risk for subsequent VTE, prophylactic anticoagulants should be considered in these patients.


The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus

Ihadaddene R, Yokom DW, Le Gal G, Moretto P, Canil CM, Delluc A, Reaume N, Carrier M.

J Thromb Haemost. 2014 Apr 4. [Epub ahead of print]


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre


URO ONCO is made possible by an unrestricted educational grant from:

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.

The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views.